Described herein are compounds and pharmaceutical compositions containing such compounds which are prodrugs of ALOX-15 inhibitors. Also described herein are methods for using such compounds in the treatment of disease.
C07D 231/10 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
C07D 231/14 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Disclosed herein are compositions comprising modified oligonucleotides. In some embodiments, the oligonucleotide includes a hydrophobic moiety. In some embodiments, the oligonucleotide includes a vinyl phosphonate. In some embodiments, the oligonucleotide includes modified oligonucleotide sugars such as 2' modified ribose molecules. In some embodiments, the oligonucleotide includes modified internucleoside linkages such as phosphorothioate linkages. In some embodiments, the oligonucleotide includes an siRNA. In some embodiments, the siRNA comprises a duplex region with overhangs on either end.
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Disclosed herein are compositions comprising an oligonucleotide that targets target. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Further provided herein are siRNA modification patterns.
Disclosed herein are compositions comprising an oligonucleotide that targets HGFAC. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating cancer that include providing an oligonucleotide that targets HGFAC in a subject.
Disclosed herein are compositions comprising an oligonucleotide that targets FGG. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating a mental disorder, or a condition associated with an FGG mutation. The method may include providing an oligonucleotide to a subject that targets FGG.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Disclosed herein are compositions comprising an oligonucleotide that targets FGG. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating a mental disorder, or a condition associated with an FGG mutation. The method may include providing an oligonucleotide to a subject that targets FGG.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Disclosed herein are compositions comprising an oligonucleotide that targets MST1. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating conditions associated with MST1 variants that include providing an oligonucleotide that targets MST1 to a subject.
Disclosed herein are compositions comprising an oligonucleotide that targets MST1R. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating conditions associated with MST1R mutations that include providing an oligonucleotide that targets MST1R to a subject.
Disclosed herein are compositions comprising an oligonucleotide that targets MS1. The oligonucleotide may include a small interfering RNA (siRNA) or art antisense oligonucleotide (ASO). Also provided herein are methods of treating conditions associated with MST1 mutations that include providing an oligonucleotide that targets MST1 to a subject.
Disclosed herein are compositions comprising an oligonucleotide that targets FGG. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating a hearing disorder related to FGG. The method may include providing an oligonucleotide to a subject that targets FGG.
11.
TREATMENT OF MTRES1 RELATED DISEASES AND DISORDERS
Disclosed herein are compositions comprising an oligonucleotide that targets MTRES1. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating conditions associated with MTRES1 gene mutations that include providing an oligonucleotide that targets MTRES1 in a subject.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Disclosed herein are compositions comprising an oligonucleotide that targets DKK2. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of decreasing DKK2 expression by providing an oligonucleotide that targets DKK2 to a subject in need thereof. Some embodiments include methods of treating hair loss by providing the oligonucleotide.
Disclosed herein are compositions comprising an oligonucleotide that targets PLIN1. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating conditions associated with PLIN1 gene mutations that include providing an oligonucleotide that targets PLIN1 in a subject.
Disclosed herein are compositions comprising an oligonucleotide that targets MST1. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating conditions associated with MST1 mutations that include providing an oligonucleotide that targets MST1 to a subject.
Provided are compositions comprising an oligonucleotide that targets Angiopoietin-like 4 (ANGPTL4). The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Oligonucleotide modification patterns are included that may be used to improve their stability or efficacy. Also provided herein are methods of treating a cardiometabolic disorder by providing an oligonucleotide that targets ANGPTL4 to a subject in need thereof. Some embodiments include treating a subject with hepatic steatosis or another cardiometabolic disorder.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Provided herein are specific inhibitors, compositions, methods and uses for reducing expression of COASY in a cell or individual. Such specific inhibitors, compositions, and methods are useful to treat a liver disease or disorder, including but not limited to NASH, in a subject.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Disclosed herein are compositions comprising an oligonucleotide that targets DKK2. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of decreasing DKK2 expression by providing an oligonucleotide that targets DKK2 to a subject in need thereof. Some embodiments include methods of treating hair loss by providing the oligonucleotide.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
A61Q 7/00 - Preparations for affecting hair growth
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
Disclosed herein are compositions comprising an oligonucleotide that targets MST1. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating conditions associated with MST1 mutations that include providing an oligonucleotide that targets MST1 to a subject.
Provided herein, are compositions comprising GalNAc moieties that may be conjugated to an oligonucleotide. The oligonucleotide may be a small interfering RNA or an antisense oligonucleotide. Also provided herein are methods of treatment that include administering the composition to a subject.
Disclosed herein are compositions comprising a small molecule that targets MTRES1. Also provided herein are methods of treating conditions associated with MTRES1 gene mutations that include providing a small molecule that targets MTRES1 in a subject.
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
23.
GENE THERAPY TREATMENT OF MTRES1 RELATED DISEASES AND DISORDERS
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations for preventing or treating diseases of the cardiovascular system, diseases of the endocrine system, diseases of the gastrointestinal and digestive system, diseases of aging, diseases of the blood, diseases of the brain, diseases of the ear, nose and throat, diseases of the liver, diseases of the kidney, diseases of the nervous system, cancer, metabolic diseases, diseases of the immune system, diseases of the respiratory system, diseases of the musculoskeletal system, diseases of the genitourinary system, diseases of the skin, diseases of the eye, diseases of the auditory system, diseases of the reproductive system, diseases of pregnancy, psychiatric diseases, nutritional diseases, hereditary diseases, allergic diseases and infectious diseases; pharmaceutical preparations for use in angiology, cardiology, endocrinology, gastroenterology, genetics, geriatrics, gynecology, hematology, hepatology, immunology, nephrology, neurology, obstetrics, oncology, pulmonology, pneumology, respirology, rheumatology, anesthesiology, urology, dermatology, gynecology, orthopedics, ophthalmology, infectiology, and psychiatry, particularly for preventing or treating diseases of the cardiovascular system, diseases of the endocrine system, diseases of the gastrointestinal and digestive system, diseases of aging, diseases of the blood, diseases of the brain, diseases of the ear, nose and throat, diseases of the liver, diseases of the kidney, diseases of the nervous system, cancer, metabolic diseases, diseases of the immune system, diseases of the respiratory system, diseases of the musculoskeletal system, diseases of the genitourinary system, diseases of the skin, diseases of the eye, diseases of the auditory system, diseases of the reproductive system, diseases of pregnancy, psychiatric diseases, nutritional diseases, hereditary diseases, allergic diseases and infectious diseases; pharmaceutical preparations for use in pediatric, adolescent, adult, geriatric, inpatient, outpatient, acute, emergency, family, and preventative medicine, particularly for preventing or treating diseases of the cardiovascular system, diseases of the endocrine system, diseases of the gastrointestinal and digestive system, diseases of aging, diseases of the blood, diseases of the brain, diseases of the ear, nose and throat, diseases of the liver, diseases of the kidney, diseases of the nervous system, cancer, metabolic diseases, diseases of the immune system, diseases of the respiratory system, diseases of the musculoskeletal system, diseases of the genitourinary system, diseases of the skin, diseases of the eye, diseases of the auditory system, diseases of the reproductive system, diseases of pregnancy, psychiatric diseases, nutritional diseases, hereditary diseases, allergic diseases and infectious diseases; pharmaceutical preparations for the treatment of infectious, deficiency, excess, acquired, idiopathic, iatrogenic, genetic, hereditary, and physiological diseases; medical test kits comprising chemical reagents and preparations for medical use in connection with the detection of gene mutations, gene expression profiles, and other molecular abnormalities, indicators, and markers for use in prognosing or predicting progression and severity of disease and predisposition to developing disease and for use in evaluating and selecting therapy or treatment regimens; medical diagnostic reagents, assays, preparations, and diagnostic test kits consisting primarily of reagents for medical diagnostic purposes, namely, testing of fluids; chemical reagents for medical use in connection with the detection of gene mutations, gene expression profiles, and other molecular abnormalities, indicators, and markers for use in prognosing or predicting progression and severity of disease and predisposition to developing disease and for use in evaluating and selecting therapy or treatment regimens; diagnostic test kits comprised of chemical reagents and preparations for medical use in connection with the detection of gene mutations, gene expression profiles, and other molecular abnormalities, indicators, and markers for use in prognosing or predicting progression and severity of disease and predisposition to developing disease and for use in evaluating and selecting therapy or treatment regimens; diagnostic kits consisting primarily of reagents for body fluid analysis and nucleic acid analysis and for detecting genetic conditions, disorders, and diseases for medical use; Diagnostic reagents for medical use; diagnostic reagents for clinical or medical laboratory use; reagents and containers specifically adapted for reagents, namely, reagents comprising paramagnetic beads for use in the processing, purification, and cleanup of samples containing genomic material, including material from single cells, for medical purposes; diagnostic chemical test kits consisting primarily of monoclonal antibodies, buffers, and reagents for medical use; medical test kits comprised of medical diagnostic reagents and assays for high-quality single-cell and low-input dna amplification, primary template-directed amplification (pta) reaction and library cleanup, optimum bead cleanup performance, single-cell and low-input transcriptional profiling, and combined genome and transcriptome profiling; medical test kits comprised of medical diagnostic reagents for use in the amplification and recovery of genomic material, including genomic material from single cells; kits comprising reagents, namely, reagents for medical use comprising paramagnetic beads for use in the processing, purification, and cleanup of samples containing genomic material, including material from single cells; medical test kits comprised of medical diagnostic reagents for use in connection with next-generation sequencing (ngs) for the purpose of revealing the presence and quantity of rna and analyzing cellular transcriptome; medical test kits comprised of medical diagnostic reagents for genetic sequencing of messenger ribonucleic acid (mrna), complementary dna (cdna), and full-length transcripts; diagnostic kits comprising reagents for medical use; diagnostic kits comprising reagents for drug target discovery; Agents, reagents, assays, enzymes, nucleotides, buffers, chemical preparations, and biological preparations for medical, dental, and veterinary use; Diagnostic reagents and preparations for medical, dental, and veterinary use; Clinical diagnostic reagents; Biological preparations for medical, dental, and veterinary use; Goods for use in the treatment of illness and disease being biological and chemical preparations, agents, reagents, assays, enzymes, nucleotides, and buffers, for medical, dental, and veterinary purposes; Bacterial preparations for medical, dental and veterinary use; Biological tissue cultures for medical, dental, and veterinary use; Blood for medical purposes; Parasiticides; Kits comprised of nucleotides, reagents, enzymes, agents, assays, buffers, chemical preparations, or biological preparations for medical purposes; Kits comprised of nucleotides, reagents, enzymes, agents, assays, buffers, chemical preparations, or biological preparations for medical genetic testing and medical diagnostic purposes; Agents, reagents, assays, enzymes, nucleotides, buffers, chemical preparations, and biological preparations for medical, dental and veterinary use, including in the fields of medical diagnostics, clinical diagnostics, companion diagnostics, veterinary diagnostics, dental diagnostics, medical forensics, laboratory medicine; Agents, reagents, assays, enzymes, nucleotides, buffers, chemical preparations, and biological preparations for medical, dental and veterinary use, including in the fields of veterinary medicine, genetic testing, nucleic acid sequencing, genetics, cosmetics, dermatology, oncology, prenatal screening and testing; diseases, forensics, in vitro diagnostics, infectious diseases; Agents, reagents, assays, enzymes, nucleotides, buffers, chemical preparations, and biological preparations for medical, dental and veterinary use, including in the fields of reproductive health, neonatal intensive care, personalized medicine, microbiology, biology, biotechnology, metagenomics, pharmaceuticals, dietary supplements, fungicide development, herbicide development, and drug development; Kits comprised of enzyme substrates for medical genetic testing and medical diagnostic purposes; Pharmaceutical preparations; Medical and veterinary preparations.. Pharmaceutical research in connection with human genetics and programmable biology; pharmaceutical research in the fields of angiology, cardiology, endocrinology, gastroenterology, geriatrics, hematology, hepatology, nephrology, neurology, oncology, pulmonology, pneumology, respirology, rheumatology, anesthesiology, urology, dermatology, gynecology, ophthalmology, infectiology, and psychiatry; pharmaceutical research in the fields of pediatric, geriatric, emergency, family, and preventative medicine; pharmaceutical research in the field of treatment of infectious, deficiency, hereditary, and physiological diseases; medical research in connection with various diseases and disorders, including eosinophilic diseases, asthma, CRS, and allergic rhinitis, autoimmune diseases, including psoriasis, vitiligo, and lichen planus, ocular diseases, including intraocular pressure and glaucoma, and atopic dermatitis; clinical research in the field of genetics directed to the evaluation of genetic variants; clinical research in human genetics; statistical analysis relating to scientific research in the field of human genetics and genetic variation; design and development of statistical algorithms for use in the field of human genetics and evaluation of genetic variations; statistical analysis for determining deleterious genetic variations in the field of human genetics, for scientific research purposes; clinical trial research and laboratory research services for the further purpose of drug discovery services, pharmaceutical research services, pre-clinical medical research screening, and clinical trial, research and evaluation services; biosignatures, genomics, proteomics and pharmacology research services; development of disease models for use in evaluation of drugs and discovery of new drugs; drug discovery, drug screening for scientific research purposes, pre-clinical research and trials for pharmaceutical development purposes; and research and development of new diagnostic products and pharmaceutical drug services for others; biochemical analysis services, namely, evaluation of non-genetic biological response to disease, drugs, and the environment; providing temporary use of non-downloadable computer software for customizing, selecting, and ordering health and genetic analysis and diagnostic kits and assays and for accessing, viewing, and storing health and genetic information via electronic, optical, and wireless communication networks; scientific research analysis and consulting services which use bioinformatics; Genomic analysis and sequencing services for scientific and research purposes; genomic analysis and sequencing services for precision and personalized medicine; medical and scientific research in the fields of genetics, genomics, proteomics, transcriptomics, epigenomics, metabolomics, meta-genomics, meta-transcriptomics, and microbiomics; medical and scientific research in connection with circulating tumor cells (ctc), cell free dna (cfdna), circulating tumor dna (ctdna), cancer genomics, methylome, methylomics, and dna methylation; nucleic acid and ribonucleic acid analysis services for scientific research purposes; providing medical and scientific research information in the fields of genetics, genomics, proteomics, transcriptomics, epigenomics, metabolomics, meta-genomics, meta-transcriptomics, and microbiomics; medical and scientific research in connection with high-quality single-cell and low-input dna amplification, primary template-directed amplification (pta) reaction and library cleanup, optimum bead cleanup performance, single-cell and low-input transcriptional profiling, and combined genome and transcriptome profiling; medical and scientific research in connection with genome amplification to detect genetic variants in cells; medical and scientific research in connection with measuring genetic diversity in single cells; medical and scientific research in connection with primary template-directed amplification for use in connection with single cells and ultra-low dna input samples; medical and scientific research for the purpose of elevating single cell genome variants for the purpose of genome amplification; dna analysis and sequencing services for scientific and research purposes; research, development and scientific consultancy in the field of genomics; medical research, namely, compiling data for research purposes in the field of genomics; providing medical research information in the field of genomics, gene therapy, cell therapy for medical purposes; providing on-line non-downloadable software for collecting, analyzing, reporting, and tracking data and information in the fields of genetics, genomics, proteomics, transcriptomics, epigenomics, metabolomics, meta-genomics, meta-transcriptomics, and microbiomics; Scientific, biological, and medical research; Services for scientific and research purposes; Medical research; Medical research services; Providing non-downloadable computer software; Providing on-line non-downloadable computer search engine software; Providing online non-downloadable computer software for the custom design and ordering of medical, medical diagnostic, medical treatment and medical research goods, assays, agents, enzymes, nucleotides, nucleic acids, buffers, chemical preparations, biological preparations, reagents, instruments and apparatus; Software as a service (SaaS) services; Platform as a service (PaaS) services; Software as a service (SaaS) and platform as a service (PaaS), including hosting software for use by others for use in the custom design and ordering of medical, medical diagnostic, medical treatment and medical research goods, assays, agents, enzymes, nucleotides, nucleic acids, buffers, chemical preparations, biological preparations, reagents, instruments and apparatus, in the fields of diagnostics, companion diagnostics, medical diagnostics; Software as a service (SaaS) and platform as a service (PaaS), including hosting software for use by others for use in the custom design and ordering of medical treatment, medical research, clinical diagnostics, clinical research, veterinary diagnostics, veterinary research, dental diagnostics, dental research, medical forensics, medical laboratory research, laboratory medicine; Software as a service (SaaS) and platform as a service (PaaS), including hosting software for use by others for use in the custom design and ordering of veterinary medicine, veterinary science, genetic testing, nucleic acid sequencing, genetics, genotyping, life sciences, agriculture, food safety, cosmetics, dermatology, oncology, prenatal screening and testing, diseases, forensics, in vitro diagnostics, infectious diseases, reproductive health, neonatal intensive care; Software as a service (SaaS) and platform as a service (PaaS), including hosting software for use by others for use in the custom design and ordering of personalized medicine, microbiology, biology, biotechnology, metagenomics, pharmaceuticals, dietary supplements, dietary supplement development, fungicide development, herbicide development, drug development and disease treatment; Software as a service (SaaS) services and platform as a service (PaaS) for use with diagnostics, companion diagnostics, medical diagnostics, medical treatment, medical research, clinical diagnostics, clinical research, veterinary diagnostics, veterinary research, dental diagnostics, dental research; Software as a service (SaaS) services and platform as a service (PaaS) for use with medical forensics, medical laboratory research, laboratory medicine, veterinary medicine, veterinary science, genetic testing, genetics, genotyping, life sciences, agriculture, food safety, cosmetics, dermatology, oncology, prenatal screening and testing, diseases, forensics, in vitro diagnostics, infectious diseases; Software as a service (SaaS) services and platform as a service (PaaS) for use with reproductive health, neonatal intensive care, personalized medicine, microbiology, biology, biotechnology, metagenomics, pharmaceuticals, dietary supplements, dietary supplement development, fungicide development, herbicide development, drug development and disease treatment; Software as a service (SaaS) services and platform as a service (PaaS) services for collecting, storing, analyzing, sharing and reporting biological, genetic, clinical, medical, and diagnostic information, and for sample tracking and managing projects, laboratory workflow and data; Hosting an online network service that enables users to store, analyze and share data in the fields of diagnostics, companion diagnostics, medical diagnostics, medical treatment, medical research, clinical diagnostics, clinical research, veterinary diagnostics, veterinary research, dental diagnostics, dental research, medical forensics, medical laboratory research, laboratory medicine; Hosting an online network service that enables users to store, analyze and share data in the fields of veterinary medicine, veterinary science, genetic testing, nucleic acid sequencing, genetics, genotyping, life sciences, agriculture, food safety, cosmetics, dermatology, oncology, prenatal screening and testing, diseases, forensics, in vitro diagnostics, infectious diseases; Hosting an online network service that enables users to store, analyze and share data in the fields of reproductive health, neonatal intensive care, personalized medicine, microbiology, biology, biotechnology, metagenomics, pharmaceuticals, dietary supplements, dietary supplement development, fungicide development, herbicide development, drug development and disease treatment; Nucleic acid sequencing and analysis services for scientific and research purposes; Genome sequencing and analysis services for scientific and research purposes; Genetic analysis and reporting services for scientific and research purposes; Installation and maintenance of computer software, databases, and database applications for others; Installation and maintenance of computer software and database applications for others for use in the fields of diagnostics, companion diagnostics, medical diagnostics, medical treatment, medical research, clinical diagnostics, clinical research, veterinary diagnostics, veterinary research, dental diagnostics, dental research, medical forensics, medical laboratory research, laboratory medicine, veterinary medicine; Installation and maintenance of computer software and database applications for others for use in the fields of veterinary science, genetic testing, genetics, nucleic acid sequencing, genotyping, life sciences, agriculture, food safety, cosmetics, dermatology, oncology, prenatal screening and testing, diseases, forensics, in vitro diagnostics, infectious diseases, reproductive health, neonatal intensive care; Installation and maintenance of computer software and database applications for others for use in the fields of personalized medicine, microbiology, biology, biotechnology, metagenomics, pharmaceuticals, dietary supplements, dietary supplement development, fungicide development, herbicide development, drug development and disease treatment; Clinical diagnostic and consultation services in the fields of diagnostics, companion diagnostics, medical diagnostics, medical treatment, medical research, clinical diagnostics, clinical research, veterinary diagnostics, veterinary research, dental diagnostics, dental research, medical forensics, medical laboratory research, laboratory medicine; Clinical diagnostic and consultation services in the fields of veterinary medicine, veterinary science, genetic testing, genetics, nucleic acid sequencing, genotyping, life sciences, agriculture, food safety, cosmetics, dermatology, oncology, prenatal screening and testing, diseases, forensics, in vitro diagnostics, infectious diseases; Clinical diagnostic and consultation services in the fields of reproductive health, neonatal intensive care, personalized medicine, microbiology, biology, biotechnology, metagenomics, pharmaceuticals, dietary supplements, dietary supplement development, fungicide development, herbicide development, drug development and disease treatment; Scientific and technological services and research relating thereto; Scientific laboratory services; Medical laboratory services; Computer services; Computer services, including cloud hosting provider services and onsite provider services for storing, analyzing and sharing information in the fields of diagnostics, companion diagnostics, medical diagnostics, medical treatment, medical research, clinical diagnostics, clinical research, veterinary diagnostics, veterinary research, dental diagnostics, dental research, medical forensics,medical laboratory research, laboratory medicine; Computer services, including cloud hosting provider services and onsite provider services for storing, analyzing and sharing information in the fields of veterinary medicine, veterinary science, genetic testing, nucleic acid sequencing, genetics, genotyping, life sciences, agriculture, food safety, cosmetics, dermatology, oncology, prenatal screening and testing, diseases, forensics, in vitro diagnostics, infectious diseases; Computer services, including cloud hosting provider services and onsite provider services for storing, analyzing and sharing information in the fields of reproductive health, neonatal intensive care, personalized medicine, microbiology, biology, biotechnology, metagenomics, pharmaceuticals, dietary supplements, dietary supplement development, fungicide development, herbicide development, drug development and disease treatment; Providing an online network service that enables users to store, access, manage, analyze and share data for use in the fields of diagnostics, companion diagnostics, medical diagnostics, medical treatment, medical research, clinical diagnostics, clinical research, veterinary diagnostics, veterinary research, dental diagnostics, dental research, medical forensics, medical laboratory research, laboratory medicine; Providing an online network service that enables users to store, access, manage, analyze and share data for use in the fields of veterinary medicine, veterinary science, genetic testing, genetics, nucleic acid sequencing, genotyping, life sciences, agriculture, food safety, cosmetics, dermatology, oncology, prenatal screening and testing, diseases, forensics, in vitro diagnostics, infectious diseases; Providing an online network service that enables users to store, access, manage, analyze and share data for use in the fields of reproductive health, neonatal intensive care, personalized medicine, microbiology, biology, biotechnology, metagenomics, pharmaceuticals, dietary supplements, dietary supplement development, fungicide development, herbicide development, drug development and disease treatment; Design and development of automated laboratory apparatus, laboratory equipment, and computer systems for others; Providing consulting services for others relating to data management and information technology infrastructure development; Proof of concept services for others, including scientific and technical consulting and research services relating to experiment design, library preparation, library preparation quality control, sample tracking, sample quality control, and preparation of customized protocols and user guides; Design and preparation of databases for others for collecting, storing, analyzing, and reporting biological information; Computer diagnostic services in analyzing and sequencing nucleic acids and other biological molecules and materials; Development of automated laboratory equipment and systems, and computer hardware for collecting, storing, analyzing, sharing and reporting biological, genetic, clinical, medical, and diagnostic and treatment information, and for sample tracking and managing projects, laboratory workflow and data to the order and specification of others; Technical support services; Technical support services, including infrastructure management services for monitoring, administration and management of cloud computing IT and application systems in the fields of diagnostics, clinical diagnostics, medical diagnostics, medical treatment, medical research, clinical diagnostics, clinical research, veterinary diagnostics, veterinary research, dental diagnostics, dental research, medical forensics, medical laboratory research, laboratory medicine; Technical support services, including infrastructure management services for monitoring, administration and management of cloud computing IT and application systems in the fields of veterinary medicine, veterinary science, genetic testing, nucleic acid sequencing, genetics, genotyping, life sciences, agriculture, food safety, cosmetics, dermatology, oncology, prenatal screening and testing, diseases, forensics, in vitro diagnostics, infectious diseases; Technical support services, including infrastructure management services for monitoring, administration and management of cloud computing IT and application systems in the fields of reproductive health, neonatal intensive care, personalized medicine, microbiology, biology, biotechnology, metagenomics, pharmaceuticals, dietary supplements, dietary supplement development, fungicide development, herbicide development, drug development and disease treatment; Testing, analysis, and evaluation of the knowledge, skills and abilities of others in the fields of medical diagnostics, veterinary diagnostics, clinical diagnostics, companion diagnostics, medical research, medical treatment, veterinary research, dental diagnostics, dental research, diagnostics, clinical research, drug development, disease treatment, pharmaceuticals, dietary supplements; Testing, analysis, and evaluation of the knowledge, skills and abilities of others in the fields of dietary supplement development, fungicide development, herbicide development, life sciences, biology, microbiology, biotechnology, metagenomics, genetic testing, nucleic acid sequencing, and genetics to determine conformity with certification standards; Updating of computer software for others; Cloud computing featuring software; Biological material analysis services; Database design and development; DNA analysis services for the identification and treatment of illness and disease; Non-downloadable data compression and decompression software; Non-downloadable computer software for compressing and decompressing data and files; Non-downloadable computer software for encrypting data and files; Non-downloadable computer software for maximizing data and file storage; Non-downloadable computer software for use in file compression, file decompression, archiving, and computer file management; Non-downloadable computer software for accessing and decompressing archives stored in files, and then viewing and downloading one or more decompressed individual files stored inside the original compressed files archive; Non-downloadable computer software for creating a compressed file archive containing one or more user-selected individual files; Non-downloadable computer software for copying, deleting, comparing, managing, organizing, compressing, decompressing, restoring, repairing, creating, storing, synchronizing, securing and archiving of data and files; Software as a service (SaaS) featuring non-downloadable software for use in the fields of diagnostics, companion diagnostics, medical diagnostics, medical treatment, medical research, clinical diagnostics, clinical research, veterinary diagnostics, veterinary research, dental diagnostics, dental research, medical forensics, medical laboratory research; Software as a service (SaaS) featuring non-downloadable software for use in the fields of laboratory medicine, veterinary medicine, veterinary science, genetic testing, nucleic acid sequencing, genetics, genotyping, life sciences, agriculture, food safety cosmetics, dermatology, oncology, prenatal screening and testing, diseases, forensics, in vitro diagnostics, infectious diseases, reproductive health, neonatal intensive care; Software as a service (SaaS) featuring non-downloadable software for use in the fields of personalized medicine, microbiology, biology, biotechnology, metagenomics, pharmaceuticals, dietary supplements, dietary supplement development, fungicide development, herbicide development, drug development and disease treatment; Non-downloadable computer software for compressing and decompressing genomic data files; Non-downloadable computer software for analysis of sequencing data in the fields of nucleic acid sequencing, genotyping, genetic testing, and genetics; Non-downloadable computer software for analyzing next-generation sequencing (NGS) data; Non-downloadable computer software for analyzing next-generation sequencing (NGS) data in the fields of diagnostics, companion diagnostics, medical diagnostics, medical treatment, medical research, clinical diagnostics, clinical research, veterinary diagnostics, veterinary research, dental diagnostics, dental research, medical forensics, medical laboratory research, laboratory medicine; Non-downloadable computer software for analyzing next-generation sequencing (NGS) data in the fields of veterinary medicine, veterinary science, genetic testing, nucleic acid sequencing, genetics, genotyping, life sciences, agriculture, food safety, cosmetics, dermatology, oncology, prenatal screening and testing, diseases, forensics, in vitro diagnostics, infectious diseases; Non-downloadable computer software for analyzing next-generation sequencing (NGS) data in the fields of reproductive health, neonatal intensive care, personalized medicine, microbiology, biology, biotechnology, metagenomics, pharmaceuticals, dietary supplements, dietary supplement development, fungicide development, herbicide development, drug development and disease treatment; Non-downloadable computer software for capturing, storing, accessing, displaying, sharing, compressing, migrating, and managing digital files; Non-downloadable computer software for processing, visualizing, storing, sharing, and manipulating genetic data and next-generation sequencing (NGS) data; Non-downloadable computer software that enables users to store, access, manage, analyze and share data; Providing scientific analysis in the field of genetics and next-generation sequencing (NGS); Providing scientific analysis of genomic data; Cloud hosting provider services for storing, analyzing and sharing information; Non-downloadable computer software for use with genomic data; Cloud based software for providing security and privacy; Software as a service (SaaS) and Platform as a service (PaaS) services for enabling multi-omics analysis; Software as a service (SaaS) and Platform as a service (PaaS) services for use in the field of data science; Computer services, namely, providing on-line non-downloadable software for creating and sharing interactive graphical user interfaces in the nature of dashboard visualizations; Software as a service (SaaS) services, featuring software for a user interface designed to enable access to application and server infrastructure performance management with a dashboard for software application and computing infrastructure performance metrics and events for aggregation, manipulation, graphing and reporting; Software as a service (SaaS) services featuring software for enabling user interaction with genomics data via a graphical user interface; Software as a service (SaaS) services featuring software for providing users the opportunity to interactively explore integrated genomic data and associated clinical data; Platform as a service (PaaS) featuring computer software platforms for providing decentralized computing services in the nature of securing and protecting electronic data and automating workflows; Non-downloadable graphical, command line, menu driven, form based, and natural language user interface software; Non-downloadable software for user interfaces, dashboards, and command lines; Application service provider (ASP) featuring software for providing access to multiple databases that contain aggregated results of genotyping and genetic, genomic, molecular, and biomarker data; Providing scientific analysis and informational reports based upon results of genetic, genomic, molecular, and biomarker data; Software as a service (SaaS) services featuring software for research and analysis of medical and biomedical data; Application service provider featuring application programming interface (API) software for others to build and market genetic, genomic, molecular, and biomarker data; Platform as a service (PaaS) featuring computer software platforms to gather, compile, analyze, authenticate, validate, control, protect, exchange, and modify genetic, genomic, molecular, and biomarker data; Providing browser-based online non-downloadable computer software for use in management of genetic, genomic, molecular, and biomarker data; Platform as a service (PaaS) featuring computer software platforms for the collection, use, or exchange of genetic, genomic, molecular, and biomarker data; Providing a website featuring information on DNA data; Providing software as a service (SaaS) services featuring software for employing genetic algorithms and deep learning techniques; Non-downloadable software for reporting and analyzing data; Application service provider featuring application programming interface (API) software for reporting and analyzing data; Development of proprietary bioinformatic analysis software pipelines and computer systems for collecting, storing, characterizing, sorting, viewing, and delivering genetic information; Providing scientific research data in the field of genomics, including custom, proprietary bioinformatic analysis of data generated by NGS technology or unanalyzed biological data; Providing temporary use of non-downloadable computer software for use in laboratory information management; Providing temporary use of non-downloadable software for laboratory workflow process automation, open database modeling, and integrating multiple data sources; Providing temporary use of non-downloadable computer software for storage, organization, processing, retrieval and output of sampling and testing information; Computer services, namely, cloud hosting provider services in the fields of laboratory information management, laboratory information management systems and laboratory information technology; Non-downloadable software for use in proprietary bioinformatic analysis software pipelines and computer systems; Non-downloadable software for building and customizing workflows; Non-downloadable software for use in aggregating and querying large data sets; Non-downloadable software that utilizes AI (artificial intelligence) or ML (machine learning) algorithms; Non-downloadable cloud-based software that combines genomic knowledge and AI based optimization with a genomic database; Providing temporary use of non-downloadable computer software using artificial intelligence algorithms and machine learning to support platforms that contain genetic and genomic information; Providing on-line non-downloadable software incorporating artificial intelligence and machine learning models for collecting, analyzing, assessing, interpreting and predicting genetic and genomic data or information; Providing online non-downloadable software for retrieval and correlation of genetic or genomic data; Software as a service (SaaS) services featuring software for analyzing and visualizing genetic or genomic data; Providing online non-downloadable software for use in genetic sequencer integration; Providing online non-downloadable software for use in genetic sequencer integration and for use in integrating third-party software into a single workflow; Providing online non-downloadable software for use in an integrated data science environment; Providing online non-downloadable software to analyze, manage, aggregate, mine, and explore genetic or genomic data; Providing online non-downloadable software in the nature of a modular, secure data platform for scalable multi-omics data management, analysis, and exploration; Cloud-based data management and analysis software platform that enables researchers to manage, analyze, and interpret large volumes of multi-omics data in a secure, scalable, and adaptable environment; Providing online non-downloadable software for use in streamlining genomics workflow; Providing online non-downloadable software that provides users with scalable data analysis; Providing online non-downloadable software that supports highly automated workflows and custom solutions for optimized high-throughput studies; Providing online non-downloadable data aggregation and data science software; Providing online non-downloadable omics software used for exploring large genomic data sets and discovering insights related to said data sets; Providing online non-downloadable software that provides data residency, single sign-on, audit logs, and access control capabilities; Scientific and technological services and research and design relating thereto; Industrial analysis and industrial research; Quality control and authentication services; Design and development of computer hardware and software; Nucleic acid sequencing and analysis services for use in the fields of medical research, clinical research, veterinary research, dental research, medical laboratory research; Genome sequencing and analysis services in the fields of medical research, clinical research, veterinary research, dental research, medical laboratory research; Providing information in the fields of medical research, clinical research, veterinary research, dental research, medical laboratory research; Consulting services in the fields of medical research, clinical research, veterinary research, dental research, medical laboratory research; Providing a database of information, including in the fields of medical research, clinical research, veterinary research, dental research, medical laboratory research.. Genetic testing services; genetic testing for medical purposes; genetic counseling; diagnostic services in the field of genetics, namely, the identification of genes that predispose individuals to common diseases and health disorders; medical testing, namely, providing reference and clinical laboratory tests that detect, classify, analyze, and evaluate gene mutations, gene variants, gene expression profiles, and other molecular abnormalities, indicators, and markers for use in prognosing or predicting progression and severity of disease and for use in evaluating and selecting therapy or treatment regimens; medical testing services for evaluating and selecting therapy or treatment regimens, prognosing disease, predicting disease progression or disease severity, identifying predisposition to developing disease, evaluating the efficacy or toxicity of medical treatments, and identifying risk factors of disease, molecular profiles associated with successful therapies or treatment regimens, and for classifying disease progression or severity; medical diagnostic testing, monitoring, and reporting services; internet-based health care information services; providing an internet website for medical professionals in relation to medical information in the field of hereditary cancer risk assessment and testing; providing personalized healthcare and medical information; providing personalized healthcare and medical information, namely, providing medical information and reports that will enable doctors and clinicians to select and recommend the appropriate treatment, drug, and dosage levels for patients; providing medical information and reports that will enable doctors and clinicians to select and recommend the appropriate treatment, drug, and dosage levels for patients through the use of data obtained through personalized pharmacogenetic testing, proteomics and other biological testing; providing medical information and reports that will enable doctors and clinicians to select and recommend the appropriate treatment, drug, and dosage levels for patients through the use of data obtained through individual behaviors including medication compliance, exercise diet, sleep patterns and language, epigenetic and environmental factors, and bioinformatics analysis; and consultation services related thereto; medical testing services; medical testing services, namely, providing medical tests that measure, analyze, and interpret genes and medications of patients, environmental, and other factors through an algorithm; medical testing services, namely, providing medical tests that measure, analyze, and interpret genes and medications of patients, environmental, and other factors through an algorithm that weighs the contribution of each medication's multiple pathways of absorption, distribution, metabolism, and excretion; medical testing services, namely, providing medical tests that measure, analyze, and interpret genes and medications of patients, environmental, and other factors through an algorithm that weighs the contribution of each medication's receptor activity, mechanism of action, and pathways of response; medical testing services that measure the impact of genomic changes across pathways and across multiple of patients to predict which drugs and/or treatment programs have the best opportunity for positive outcomes for patients, personalize medication/treatment selection, identify potentially harmful drug interactions, and calculate drug dosage adjustments for patients; and medical information services, namely, preparation and generation of reports for the foregoing medical testing services through proprietary software applications; medical analysis and consultation services which use bioinformatics for diagnostic or treatment purposes; providing objective, evidence-based medical information tailored to each patient's individual genetic profile to enable clinicians to prescribe individually appropriate medications; gene and tissue bank services that provide DNA samples for use in future medical and scientific research, medical and scientific educational studies, and development of new medical and scientific products and validation thereof; gene and tissue bank services that provide DNA samples for use in future medical and scientific research, medical and scientific educational studies and development of new medical and scientific products and validation thereof; Medical testing for diagnostic or treatment purposes; medical testing for precision and personalized medicine purposes; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical diagnostic testing, monitoring and reporting services; medical analysis services for diagnosis the fields of oncology, cardiology, prenatal genetic testing (pgt), neurological genetic disorders, immunology, microbiome, toxicology, and bioprocessing; medical analysis services for diagnosis in the field of gene therapy and cell therapy; medical analysis services for diagnosis in the fields of genetics, genomics, proteomics, transcriptomics, epigenomics, metabolomics, meta-genomics, meta-transcriptomics, and microbiomics; genomic analysis and sequencing services for medical purposes; nucleic acid and ribonucleic acid analysis services for medical purposes; dna analysis and sequencing services for medical purposes; Providing medical information; Medical services; Medical analysis services for diagnostic, companion diagnostics and medical treatment purposes; Medical diagnostic testing, monitoring and reporting services; Clinical diagnostic services; DNA, nucleic acid and genomic sequencing, screening, and analysis services for medical purposes; Nucleic acid sequencing and analysis services for use in the fields of diagnostics, medical diagnostics, medical treatment, clinical diagnostics, companion diagnostics, veterinary diagnostics, dental diagnostics, medical forensics; Nucleic acid sequencing and analysis services for use in the fields of laboratory medicine, veterinary medicine, veterinary science, genetic testing, nucleic acid sequencing, genetics, genotyping, life sciences, agriculture, food safety, cosmetics, dermatology, oncology, prenatal screening and testing, diseases, forensics, in vitro diagnostics, infectious diseases; Nucleic acid sequencing and analysis services for use in the fields of reproductive health, neonatal intensive care, personalized medicine, microbiology, biology, biotechnology, metagenomics, pharmaceuticals, dietary supplements, dietary supplement development, fungicide development, herbicide development, drug development and disease treatment; Genome sequencing and analysis services in the fields of diagnostics, companion diagnostics, medical diagnostics, medical treatment, clinical diagnostics, veterinary diagnostics, dental diagnostics, medical forensics, laboratory medicine; Genome sequencing and analysis services in the fields of veterinary medicine, veterinary science, genetic testing, nucleic acid sequencing, genetics, genotyping, life sciences, agriculture, food safety, cosmetics, dermatology, oncology, prenatal screening and testing, diseases, forensics, in vitro diagnostics, infectious diseases, reproductive health, neonatal intensive care; Genome sequencing and analysis services in the fields of personalized medicine, microbiology, biology, biotechnology, metagenomics, pharmaceuticals, dietary supplements, dietary supplement development, fungicide development, herbicide development, drug development and disease treatment purposes; Infectious disease identification and surveillance; Medical testing and analysis for diagnostic or treatment purposes; Charitable services, including providing genome sequencing services for medical diagnostic and treatment purposes; Providing information in the fields of diagnostics, companion diagnostics, medical diagnostics, medical treatment, clinical diagnostics, veterinary diagnostics, dental diagnostics, medical forensics, laboratory medicine; Providing information in the fields of veterinary medicine, veterinary science, genetic testing, nucleic acid sequencing, genetics, genotyping, life sciences, agriculture, food safety, cosmetics, dermatology, oncology, prenatal screening and testing, diseases, forensics, in vitro diagnostics, infectious diseases, reproductive health, neonatal intensive care; Providing information in the fields of personalized medicine, microbiology, biology, biotechnology, metagenomics, pharmaceuticals, dietary supplements, dietary supplement development, fungicide development, herbicide development, drug development and disease treatment; Consulting services in the fields of diagnostics, medical diagnostics, clinical diagnostics, veterinary diagnostics, dental diagnostics, medical forensics, laboratory medicine, veterinary medicine, veterinary science, genetic testing, nucleic acid sequencing, genetics, genotyping, life sciences, agriculture, food safety; Consulting services in the fields of cosmetics, dermatology, oncology, prenatal screening and testing, diseases, forensics, in vitro diagnostics, infectious diseases, reproductive health, neonatal intensive care, personalized medicine, microbiology, biology, biotechnology, metagenomics, pharmaceuticals, dietary supplements, dietary supplement development, fungicide development, herbicide development, drug development and disease treatment; Providing a database of information regarding the fields of diagnostics, medical diagnostics, clinical diagnostics, veterinary diagnostics, dental diagnostics, medical forensics, laboratory medicine; Providing a database of information, regarding the fields of veterinary medicine, veterinary science, genetic testing, genetics, nucleic acid sequencing, genotyping, life sciences, agriculture, food safety, cosmetics, dermatology, oncology, prenatal screening and testing, diseases, forensics, in vitro diagnostics, infectious diseases, reproductive health, neonatal intensive care; Providing a database of information regarding the fields of personalized medicine, microbiology, biology, biotechnology, metagenomics, pharmaceuticals, dietary supplements, dietary supplement development, fungicide development, herbicide development, drug development and disease treatment; Providing a website featuring information related to medical apparatus, medical instrument, medical devices, diagnostics, pharmaceuticals, dietary supplements, fungicides, herbicides, and drugs; Providing a database of information in the fields of diagnostics, companion diagnostics, medical diagnostics, medical treatment,clinical diagnostics, veterinary diagnostics, dental diagnostics, medical forensics, laboratory medicine; Providing a database of information in the fields of veterinary medicine, veterinary science, genetic testing, nucleic acid sequencing, genetics, genotyping, life sciences, agriculture, food safety, cosmetics, dermatology, oncology, prenatal screening and testing, diseases, forensics, in vitro diagnostics, infectious diseases, reproductive health, neonatal intensive care; Providing a database of information in the fields of personalized medicine, microbiology, biology, biotechnology, metagenomics, pharmaceuticals, dietary supplements, dietary supplement development, fungicide development, herbicide development, drug development and disease treatment; Providing online computer databases featuring genetic, genomic, molecular, and biomarker data; Providing online searchable databases containing medical, pharmaceutical, dietary supplement, fungicide, herbicide, biological, clinical and genomic information for medical diagnostic or treatment purposes; Nucleic acid sequencing and analysis services for medical, agriculture, horticulture, veterinary, dental, and husbandry purposes; Genome sequencing and analysis services for medical, agriculture, horticulture, veterinary, dental, and husbandry purposes; Medical genetic analysis and reporting services for diagnostic, prognostic or treatment uses; DNA, nucleic acid and genomic sequencing, and analysis services for medical purposes; Genetic analysis and reporting services for medical purposes; Veterinary services; Agriculture, aquaculture, and horticulture services..
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Pharmaceutical preparations for preventing or treating diseases of the cardiovascular system, diseases of the endocrine system, diseases of the gastrointestinal system, diseases of aging, diseases of the blood, diseases of the liver, diseases of the kidney, diseases of the nervous system, cancer, metabolic diseases, diseases of the immune system, diseases of the respiratory system, diseases of the musculoskeletal system, diseases of the genitourinary system, diseases of the skin, diseases of the eye, diseases of the auditory system, diseases of the reproductive system, psychiatric diseases, allergic diseases and infectious diseases; pharmaceutical preparations for use in angiology, cardiology, endocrinology, gastroenterology, geriatrics, gynecology, hematology, hepatology, immunology, nephrology, neurology, oncology, pulmonology, pneumology, respirology, rheumatology, anesthesiology, urology, dermatology, gynecology, ophthalmology, infectiology, and psychiatry, particularly for preventing or treating diseases of the cardiovascular system, diseases of the endocrine system, diseases of the gastrointestinal system, diseases of aging, diseases of the blood, diseases of the liver, diseases of the kidney, diseases of the nervous system, cancer, metabolic diseases, diseases of the immune system, diseases of the respiratory system, diseases of the musculoskeletal system, diseases of the genitourinary system, diseases of the skin, diseases of the eye, diseases of the auditory system, diseases of the reproductive system, psychiatric diseases, allergic diseases and infectious diseases; pharmaceutical preparations for use in pediatric, geriatric, emergency, family, and preventative medicine, particularly for preventing or treating diseases of the cardiovascular system, diseases of the endocrine system, diseases of the gastrointestinal system, diseases of aging, diseases of the blood, diseases of the liver, diseases of the kidney, diseases of the nervous system, cancer, metabolic diseases, diseases of the immune system, diseases of the respiratory system, diseases of the musculoskeletal system, diseases of the genitourinary system, diseases of the skin, diseases of the eye, diseases of the auditory system, diseases of the reproductive system, psychiatric diseases, allergic diseases and infectious diseases; pharmaceutical preparations for the treatment of infectious, deficiency, hereditary, and physiological diseases
(2) Pharmaceutical preparations for preventing or treating diseases of the digestive system, diseases of the brain, diseases of the ear, nose and throat, diseases of pregnancy, nutritional diseases, hereditary diseases; pharmaceutical preparations for use in genetics, obstetrics, orthopedics, diseases of the digestive system, diseases of the brain, diseases of the ear, nose and throat, diseases of pregnancy, nutritional diseases, hereditary diseases; pharmaceutical preparations for use in adolescent, adult, inpatient, outpatient, acute, diseases of the digestive system, diseases of the brain, diseases of the ear, nose and throat, diseases of pregnancy, nutritional diseases, hereditary diseases; pharmaceutical preparations for the treatment of excess, acquired, idiopathic, iatrogenic, genetic diseases (1) Pharmaceutical research in connection with human genetics and programmable biology; pharmaceutical research in the fields of angiology, cardiology, endocrinology, gastroenterology, geriatrics, hematology, hepatology, nephrology, neurology, oncology, pulmonology, pneumology, respirology, rheumatology, anesthesiology, urology, dermatology, gynecology, ophthalmology, infectiology, and psychiatry; pharmaceutical research in the fields of pediatric, geriatric, emergency, family, and preventative medicine; pharmaceutical research in the field of treatment of infectious, deficiency, hereditary, and physiological diseases; medical research in connection with various diseases and disorders, including eosinophilic diseases, asthma, CRS, and allergic rhinitis, autoimmune diseases, including psoriasis, vitiligo, and lichen planus, ocular diseases, including intraocular pressure and glaucoma, and atopic dermatitis; pharmaceutical research services;
26.
GALNAC COMPOSITIONS FOR IMPROVING SIRNA BIOAVAILABILITY
Provided herein, are compositions comprising GalNAc moieties that may be conjugated to an oligonucleotide. The oligonucleotide may be a small interfering RNA or an antisense oligonucleotide. Also provided herein are methods of treatment that include administering the composition to a subject.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Metabolic disorders such as liver disorders and cardiovascular disorders are widely abundant, and may affect a wide variety of people. Improved therapeutics are needed for treating these disorders. Disclosed herein are compositions comprising an oligonucleotide that targets GRAM. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating conditions associated with GRAM gene mutations that include providing an oligonucleotide that targets GRAM in a subject. Some examples of diseases that may be treated include liver diseases or cardiometabolic diseases.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
28.
TREATMENT OF MS4A4E RELATED DISEASES AND DISORDERS
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Disclosed herein are compositions comprising an oligonucleotide that targets SOS Ras/Rho guanine nucleotide exchange factor 2 (SOS2). The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating conditions associated with SOS2 mutations that include providing an oligonucleotide that targets SOS2 to a subject.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Disclosed herein are compositions comprising an oligonucleotide that targets SOS Ras/Rho guanine nucleotide exchange factor 2 (SOS2). The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating conditions associated with SOS2 mutations that include providing an oligonucleotide that targets SOS2 to a subject.
Provided herein are oligonucleotide compositions that inhibit ANGPTL7 and reduce intraocular pressure when administered to an eye. The oligonucleotide compositions contain nucleoside modifications.
Disclosed herein are compositions comprising modified oligonucleotides. In some embodiments, the oligonucleotide includes a hydrophobic moiety. In some embodiments, the oligonucleotide includes a vinyl phosphonate. In some embodiments, the oligonucleotide includes modified oligonucleotide sugars such as 2' modified ribose molecules. In some embodiments, the oligonucleotide includes modified internucleoside linkages such as phosphorothioate linkages. In some embodiments, the oligonucleotide includes an siRNA. In some embodiments, the siRNA comprises a duplex region with overhangs on either end.
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
C07D 239/28 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
33.
COMPOSITIONS AND METHODS FOR THE TREATMENT OF ANGIOPOIETIN LIKE 7 (ANGPTL7) RELATED DISEASES
Provided herein are compositions comprising an oligonucleotide that targets ANGPTL7. In some embodiments, the oligonucleotide includes modified nucleotides. In some embodiments, the oligonucleotide may be used to reduce intraocular pressure in a subject's eye.
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
C07D 239/28 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
C07H 19/067 - Pyrimidine radicals with ribosyl as the saccharide radical
Disclosed herein are compositions comprising modified oligonucleotides. In some embodiments, the oligonucleotide includes a hydrophobic moiety. In some embodiments, the oligonucleotide includes a vinyl phosphonate. In some embodiments, the oligonucleotide includes modified oligonucleotide sugars such as 2' modified ribose molecules. In some embodiments, the oligonucleotide includes modified internucleoside linkages such as phosphorothioate linkages. In some embodiments, the oligonucleotide includes an siRNA. In some embodiments, the siRNA comprises a duplex region with overhangs on either end.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
C07D 239/28 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
Disclosed herein are compositions comprising modified oligonucleotides. In some embodiments, the oligonucleotide includes a hydrophobic moiety. In some embodiments, the oligonucleotide includes a vinyl phosphonate. In some embodiments, the oligonucleotide includes modified oligonucleotide sugars such as 2′ modified ribose molecules. In some embodiments, the oligonucleotide includes modified internucleoside linkages such as phosphorothioate linkages. In some embodiments, the oligonucleotide includes an siRNA. In some embodiments, the siRNA comprises a duplex region with overhangs on either end.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
37.
GALNAC COMPOSITIONS FOR IMPROVING SIRNA BIOAVAILABILITY
Provided herein, are compositions comprising GalNAc moieties that may be conjugated to an oligonucleotide. The oligonucleotide may be a small interfering RNA or an antisense oligonucleotide. Also provided herein are methods of treatment that include administering the composition to a subject.
C07H 15/00 - Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
38.
GalNAc compositions for improving siRNA bioavailability
Provided herein, are compositions comprising GaINAc moieties that may be conjugated to an oligonucleotide. The oligonucleotide may be a small interfering RNA or an antisense oligonucleotide. Also provided herein are methods of treatment that include administering the composition to a subject.
Disclosed herein are compositions comprising an oligonucleotide that targets HGFAC. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating cancer that include providing an oligonucleotide that targets HGFAC in a subject.
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for preventing or treating diseases of the cardiovascular system, diseases of the endocrine system, diseases of the gastrointestinal and digestive system, diseases of aging, diseases of the blood, diseases of the brain, diseases of the ear, nose and throat, diseases of the liver, diseases of the kidney, diseases of the nervous system, cancer, metabolic diseases, diseases of the immune system, diseases of the respiratory system, diseases of the musculoskeletal system, diseases of the genitourinary system, diseases of the skin, diseases of the eye, diseases of the auditory system, diseases of the reproductive system, diseases of pregnancy, psychiatric diseases, nutritional diseases, hereditary diseases, allergic diseases and infectious diseases; pharmaceutical preparations for use in angiology, cardiology, endocrinology, gastroenterology, genetics, geriatrics, gynecology, hematology, hepatology, immunology, nephrology, neurology, obstetrics, oncology, pulmonology, pneumology, respirology, rheumatology, anesthesiology, urology, dermatology, gynecology, orthopedics, ophthalmology, infectiology, and psychiatry, particularly for preventing or treating diseases of the cardiovascular system, diseases of the endocrine system, diseases of the gastrointestinal and digestive system, diseases of aging, diseases of the blood, diseases of the brain, diseases of the ear, nose and throat, diseases of the liver, diseases of the kidney, diseases of the nervous system, cancer, metabolic diseases, diseases of the immune system, diseases of the respiratory system, diseases of the musculoskeletal system, diseases of the genitourinary system, diseases of the skin, diseases of the eye, diseases of the auditory system, diseases of the reproductive system, diseases of pregnancy, psychiatric diseases, nutritional diseases, hereditary diseases, allergic diseases and infectious diseases; pharmaceutical preparations for use in pediatric, adolescent, adult, geriatric, inpatient, outpatient, acute, emergency, family, and preventative medicine, particularly for preventing or treating diseases of the cardiovascular system, diseases of the endocrine system, diseases of the gastrointestinal and digestive system, diseases of aging, diseases of the blood, diseases of the brain, diseases of the ear, nose and throat, diseases of the liver, diseases of the kidney, diseases of the nervous system, cancer, metabolic diseases, diseases of the immune system, diseases of the respiratory system, diseases of the musculoskeletal system, diseases of the genitourinary system, diseases of the skin, diseases of the eye, diseases of the auditory system, diseases of the reproductive system, diseases of pregnancy, psychiatric diseases, nutritional diseases, hereditary diseases, allergic diseases and infectious diseases; pharmaceutical preparations for the treatment of infectious, deficiency, excess, acquired, idiopathic, iatrogenic, genetic, hereditary, and physiological diseases
41.
PRODRUGS OF ALOX-15 INHIBITORS AND METHODS OF USING THE SAME
Described herein are compounds and pharmaceutical compositions containing such compounds which are prodrugs of ALOX-15 inhibitors. Also described herein are methods for using such compounds in the treatment of disease.
C07D 231/10 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
C07D 231/14 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Disclosed herein are compositions comprising an oligonucleotide that targets FGG. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating a mental disorder, or a condition associated with an FGG mutation. The method may include providing an oligonucleotide to a subject that targets FGG.
Disclosed herein are compositions comprising an oligonucleotide that targets FGG. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating a mental disorder, or a condition associated with an FGG mutation. The method may include providing an oligonucleotide to a subject that targets FGG.
Provided are compositions comprising an oligonucleotide that targets Thymic stromal lymphopoietin (TSLP). The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating an airway disorder by providing an oligonucleotide that targets TSLP to a subject in need thereof. In some embodiments, the oligonucleotide targeting is specific for a long isoform of TSLP (lfTSLP).
Disclosed herein are compositions comprising an oligonucleotide that targets DKK2. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of decreasing DKK2 expression by providing an oligonucleotide that targets DKK2 to a subject in need thereof. Some embodiments include methods of treating hair loss by providing the oligonucleotide.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Disclosed herein are compositions comprising an oligonucleotide that targets MTRES1. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating conditions associated with MTRES1 gene mutations that include providing an oligonucleotide that targets MTRES1 in a subject.
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Disclosed herein are compositions comprising an oligonucleotide that targets MST1. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating conditions associated with MST1 mutations that include providing an oligonucleotide that targets MST1 to a subject.
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
A61P 11/00 - Drugs for disorders of the respiratory system
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Disclosed herein are compositions comprising an oligonucleotide that targets MST1. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating conditions associated with MST1 mutations that include providing an oligonucleotide that targets MST1 to a subject.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
51.
TREATMENT OF MTRES1 RELATED DISEASES AND DISORDERS
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
Provided are compositions comprising an oligonucleotide that targets Angiopoietin-like 4 (ANGPTL4). The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Oligonucleotide modification patterns are included that may be used to improve their stability or efficacy. Also provided herein are methods of treating a cardiometabolic disorder by providing an oligonucleotide that targets ANGPTL4 to a subject in need thereof. Some embodiments include treating a subject with hepatic steatosis or another cardiometabolic disorder.
Provided herein are specific inhibitors, compositions, methods and uses for reducing expression of COASY in a cell or individual. Such specific inhibitors, compositions, and methods are useful to treat a liver disease or disorder, including but not limited to NASH, in a subject.
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
54.
OLIGONUCLEOTIDES FOR TREATMENT OF ANGIOPOIETIN LIKE 4 (ANGPTL4) RELATED DISEASES
Provided are compositions comprising an oligonucleotide that targets Angiopoietin-like 4 (ANGPTL4). The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating a metabolic or cardiovascular disorder by providing an oligonucleotide that targets ANGPTL4 to a subject in need thereof.
Provided herein, are compositions comprising GalNAc moieties that may be conjugated to an oligonucleotide. The oligonucleotide may be a small interfering RNA or an antisense oligonucleotide. Also provided herein are methods of treatment that include administering the composition to a subject.
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
C07H 19/207 - Purine radicals with the saccharide radical being esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine-adenine dinucleotide or nicotinamide-adenine dinucleotide
Provided herein are oligonucleotide compositions that inhibit ANGPTL7 and reduce intraocular pressure when administered to an eye. The oligonucleotide compositions contain nucleoside modifications.
Molecules for inhibiting arachidonate 15-lipoxygenase (ALOX-15) gene products including dsRNA (dsRNA) agents such as small interfering RNAs (siRNAs) for therapeutic use, additionally, methods to inhibit the expression of a target gene by administering these agents for the treatment of diseases involving ALOX-15 gene products.
Described herein are compounds and pharmaceutical compositions containing such compounds which are prodrugs of ALOX-15 inhibitors. Also described herein are methods for using such compounds in the treatment of disease.
C07D 231/10 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
C07D 231/14 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
60.
Treatment of thymic stromal lymphopoietin (TSLP) related diseases by inhibition of long-form TSLP transcripts
Provided are compositions comprising an oligonucleotide that targets Thymic stromal lymphopoietin (TSLP). The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating an airway disorder by providing an oligonucleotide that targets TSLP to a subject in need thereof. In some embodiments, the oligonucleotide targeting is specific for a long isoform of TSLP (1fTSLP).
Provided are compositions comprising an oligonucleotide that targets Angiopoietin-like 4 (ANGPTL4). The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating a metabolic or cardiovascular disorder by providing an oligonucleotide that targets ANGPTL4 to a subject in need thereof.
Molecules for inhibiting arachidonate 15-lipoxygenase (ALOX-15) gene products including dsRNA (dsRNA) agents such as small interfering RNAs (siRNAs), antisense oligonucleotides, and small molecule inhibitors for therapeutic use. Additionally provided are methods to inhibit the expression of a target gene by administering these agents for the treatment of diseases involving ALOX-15 gene products.
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
Provided are compositions comprising an oligonucleotide that targets Angiopoietin-like 4 (ANGPTL4). The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating a metabolic or cardiovascular disorder by providing an oligonucleotide that targets ANGPTL4 to a subject in need thereof.
Provided are compositions comprising an oligonucleotide that targets Angiopoietin-like 4 (ANGPTL4). The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating a metabolic or cardiovascular disorder by providing an oligonucleotide that targets ANGPTL4 to a subject in need thereof.
Provided herein are oligonucleotide compositions that inhibit ANGPTL7 and reduce intraocular pressure when administered to an eye. The oligonucleotide compositions contain nucleoside modifications.
Described herein are compounds and pharmaceutical compositions containing such compounds which are prodrugs of ALOX-15 inhibitors. Also described herein are methods for using such compounds in the treatment of disease.
C07C 233/66 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
C07C 305/24 - Esters of sulfuric acids having oxygen atoms of sulfate groups bound to carbon atoms of six-membered aromatic rings of non-condensed six-membered aromatic rings
C07C 311/08 - Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
C07D 207/34 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D 209/14 - Radicals substituted by nitrogen atoms, not forming part of a nitro radical
C07D 209/42 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 213/75 - Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
C07D 263/48 - Nitrogen atoms not forming part of a nitro radical
C07D 311/30 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
A61K 31/4427 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
Described herein are compounds and pharmaceutical compositions containing such compounds which are prodrugs of ALOX-15 inhibitors. Also described herein are methods for using such compounds in the treatment of disease.
C07D 231/10 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
C07D 231/14 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
68.
Treatment of angiopoietin like 7 (ANGPTL7) related diseases
Provided herein are oligonucleotide compositions that inhibit ANGPTL7 and reduce intraocular pressure when administered to an eye. The oligonucleotide compositions contain nucleoside modifications.
Provided herein are oligonucleotide compositions that inhibit ANGPTL7 and reduce intraocular pressure when administered to an eye. The oligonucleotide compositions contain nucleoside modifications.
Provided herein are oligonucleotide compositions that inhibit ANGPTL7 and reduce intraocular pressure when administered to an eye. The oligonucleotide compositions contain nucleoside modifications.
Described herein are compounds and pharmaceutical compositions containing such compounds which are prodrugs of ALOX-15 inhibitors. Also described herein are methods for using such compounds in the treatment of disease.
C07D 231/14 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
72.
TREATMENT OF THYMIC STROMAL LYMPHOPOIETIN (TSLP) RELATED DISEASES BY INHIBITION OF LONG-FORM TSLP TRANSCRIPTS
Provided are compositions comprising an oligonucleotide that targets Thymic stromal lymphopoietin (TSLP). The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating an airway disorder by providing an oligonucleotide that targets TSLP to a subject in need thereof. In some embodiments, the oligonucleotide targeting is specific for a long isoform of TSLP (lfTSLP).
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
73.
PROCESS TO INHIBIT OR ELIMINATE EOSINOPHILIC DISEASES OF THE AIRWAY AND RELATED CONDITIONS
Molecules for inhibiting arachidonate 15-lipoxygenase (ALOX-15) gene products including dsRNA (dsRNA) agents such as small interfering RNAs (siRNAs) for therapeutic use, additionally, methods to inhibit the expression of a target gene by administering these agents for the treatment of diseases involving ALOX-15 gene products.
Molecules for inhibiting arachidonate 15-lipoxygenase (ALOX-15) gene products including dsRNA (dsRNA) agents such as small interfering RNAs (siRNAs), antisense oligonucleotides, and small molecule inhibitors for therapeutic use. Additionally provided are methods to inhibit the expression of a target gene by administering these agents for the treatment of diseases involving ALOX-15 gene products.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical research in connection with human genetics and programmable biology; pharmaceutical research in the fields of angiology, cardiology, endocrinology, gastroenterology, geriatrics, hematology, hepatology, nephrology, neurology, oncology, pulmonology, pneumology, respirology, rheumatology, anesthesiology, urology, dermatology, gynecology, ophthalmology, infectiology, and psychiatry; pharmaceutical research in the fields of pediatric, geriatric, emergency, family, and preventative medicine; pharmaceutical research in the field of treatment of infectious, deficiency, hereditary, and physiological diseases; medical research in connection with various diseases and disorders, including eosinophilic diseases, asthma, CRS, and allergic rhinitis, autoimmune diseases, including psoriasis, vitiligo, and lichen planus, ocular diseases, including intraocular pressure and glaucoma, and atopic dermatitis
